Trial Information - Phase III
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)
Disease Specifics: NSCLC
Protocol ID: J2G-MC-JZJX
Sponsor: ELI LILLY
Status: STAR Trial
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
